- Company
- AI Solution
- R&D
- Business
- Newsroom
ENG
- Company
- AI Solution
- R&D
- Business
- Newsroom
ENG
Asset Program
Ready-to-use, AI-Validated Drug Candidate Packages
The Asset Program represents a portfolio of pre-validated drug candidates verified through in silico screening
and binding affinity assay. It mitigates early discovery-stage risks while ensuring a seamless pipeline
from research and development through to commercialization.
Asset Program
Ready-to-use, AI-Validated Drug Candidate Packages
The Asset Program represents a portfolio of pre-validated drug candidates verified through in silico screening
and binding affinity assay. It mitigates early discovery-stage risks while ensuring a seamless pipeline
from research and development through to commercialization.
Why Syntekabio Asset Program
Ready-to-Go Package
Ready-to-use drug candidate packages validated through proactive discovery and in silico verification
Eliminates early-stage exploration uncertainties and enables rapid R&D initiation.
Ready-to-Go Package
Ready-to-use drug candidate packages validated through proactive discovery and in silico verification
Eliminates early-stage exploration uncertainties and enables rapid R&D initiation.
From Research to Business
Seamless execution framework from research to commercialization
Supports the entire pipeline from PoC validation through collaborative research, follow-on development, and licensing-out, enabling swift decision-making and value realization.
From Research to Business
Seamless execution framework from research to commercialization
Supports the entire pipeline from PoC validation through collaborative research, follow-on development, and licensing-out, enabling swift decision-making and value realization.
Platform-Validated Quality
Consistent, reproducible quality via a unified AI platform.
Derived from Syntekabio's proprietary AI platform and integrated analysis pipeline, it offers reliable benchmarks for subsequent research and development.
Platform-Validated Quality
Consistent, reproducible quality via a unified AI platform.
Derived from Syntekabio's proprietary AI platform and integrated analysis pipeline, it offers reliable benchmarks for subsequent research and development.
Platform-Validated Quality
Validated quality consistency powered by AI platform.
Generated through Syntekabio's proprietary AI platform and standardized analytical algorithms, ensuring reproducible and reliable data throughout subsequent research stages.
Why Syntekabio Asset Program
Ready-to-Go Package
Immediately applicable candidate package validated in silico.
Reduces uncertainties in the early discovery stage, enabling rapid progression to the subsequent development phase.
From Research to Business
Operational structure for seamless R&D to business transition.
Beyond research validation, it seamlessly transitions to the next decision-making stage, encompassing joint research, further development, and licensing discussions.
Platform-Validated Quality
Consistent, reproducible quality via a unified AI platform.
Derived from Syntekabio's proprietary AI platform and integrated analysis pipeline, it offers reliable benchmarks for subsequent research and development.
Why Syntekabio Asset Program
Ready-to-Go Package
Immediately applicable candidate package validated in silico.
Reduces uncertainties in the early discovery stage, enabling rapid progression to the subsequent development phase.
From Research to Business
Operational structure for seamless R&D to business transition.
Beyond research validation, it seamlessly transitions to the next decision-making stage, encompassing joint research, further development, and licensing discussions.
Platform-Validated Quality
Consistent, reproducible quality via a unified AI platform.
Derived from Syntekabio's proprietary AI platform and integrated analysis pipeline, it offers reliable benchmarks for subsequent research and development.
Asset Program List
Small Molecule
Antibody
SM-ARS®
No
Target Protein
Indications
Mechanism of Action
Marketed drugs / Pipeline Drugs
1
BCL2
Hematologic malignancies (CLL, AML, etc.)
Inhibition of apoptosis-regulating protein
Venetoclax
2
BTK
B-cell lymphoma, Autoimmune diseases
Inhibition of B-cell receptor signaling
Ibrutinib, Acalabrutinib, Zanubrutinib
3
CDK2/4/6
Breast cancer, Solid tumors
Inhibition of cell cycle progression
Palbociclib, Ribociclib, Abemaciclib
4
FGFR1/2/3
Cholangiocarcinoma, Bladder cancer, etc.
Inhibition of FGFR signaling
Erdafitinib, Pemigatinib, Futibatinib
5
KRAS
Non-small cell lung cancer, Colorectal cancer
Inhibition of KRAS G12C mutation
Sotorasib, Adagrasib
6
MCLI
Hematologic malignancies
Inhibition of anti-apoptotic protein
S64315, AMG 176
7
MDM2
Solid tumors, Hematologic malignancies
Inhibition of p53 degradation → Activation of tumor suppression
Idasanutlin, BI-907828
8
PIK3CA
Breast cancer, Lymphoma
Inhibition of PI3K-AKT pathway
Alpelisib, Copanlisib
9
TYK2
Psoriasis, Lupus
Selective inhibition of TYK2 in JAK-STAT pathway
Deucravacitinib
10
EGFR
Non-small cell lung cancer, Colorectal cancer
Inhibition of EGFR signaling
Osimertinib, Erotinib, Gefitinib
11
JAK1/2/3/TEC
Autoimmune diseases, Myelofibrosis
Inhibition of JAK/STAT pathway
Rusolitinib, Tofacitinib, Baricitinib
12
NLRP3
Inflammatory diseases
Inhibition of inflammasome
DFV890, Inzomelid
13
ROCK1/2
Fibrosis, Glaucoma
Inhibition of cytoskeleton regulatory pathway
Netarsudil, Ripasudil
14
S1PR1
Multiple sclerosis
Inhibition of lymphocyte migration
Fingolimod, Ozanimod
15
GLP1R
Type 2 diabetes, Obesity
GLP-1 receptor agonism → Promotion of insulin secretion
Semaglutide, Tirzepatide
16
MAPT
Alzheimer's disease, Parkinson's disease
Inhibition of Tau protein aggregation
TAU360, LMTM
17
PDE10A
Schizophrenia, Parkinson's disease
Regulation of dopamine signaling
Papaverine derivatives
18
KCNQ2/3
Epilepsy
Regulation of neuronal excitability
Ezogabine
19
PDE4/4A/4B/4D/4C
Inflammatory and psychiatric disorders
Inhibition of cAMP degradation → Anti-inflammatory effect
Roflumilast, Apremilast
20
PCSK9
Dyslipidemia
Inhibition of LDL receptor degradation
MK-0616 (oral PCSK9i)
Small Molecule
Antibody
SM-ARS®
No
Target Protein (Gene)
Indications
Mechanism of Action
Marketed drugs / Pipeline Drugs
1
BCL2
Hematologic malignancies (CLL, AML, etc.)
Inhibition of apoptosis-regulating protein
Venetoclax
2
BTK
B-cell lymphoma, Autoimmune diseases
Inhibition of B-cell receptor signaling
Ibrutinib, Acalabrutinib, Zanubrutinib
3
CDK2/4/6
Breast cancer, Solid tumors
Inhibition of cell cycle progression
Palbociclib, Ribociclib, Abemaciclib
4
FGFR1/2/3
Cholangiocarcinoma, Bladder cancer, etc.
Inhibition of FGFR signaling
Erdafitinib, Pemigatinib, Futibatinib
5
KRAS
Non-small cell lung cancer, Colorectal cancer
Inhibition of KRAS G12C mutation
Sotorasib, Adagrasib
6
MCLI
Hematologic malignancies
Inhibition of anti-apoptotic protein
S64315, AMG 176
7
MDM2
Solid tumors, Hematologic malignancies
Inhibition of p53 degradation → Activation of tumor suppression
Idasanutlin, BI-907828
8
PIK3CA
Breast cancer, Lymphoma
Inhibition of PI3K-AKT pathway
Alpelisib, Copanlisib
9
TYK2
Psoriasis, Lupus
Selective inhibition of TYK2 in JAK-STAT pathway
Deucravacitinib
10
EGFR
Non-small cell lung cancer, Colorectal cancer
Inhibition of EGFR signaling
Osimertinib, Erotinib, Gefitinib
11
JAK1/2/3/TEC
Autoimmune diseases, Myelofibrosis
Inhibition of JAK/STAT pathway
Rusolitinib, Tofacitinib, Baricitinib
12
NLRP3
Inflammatory diseases
Inhibition of inflammasome
DFV890, Inzomelid
13
ROCK1/2
Fibrosis, Glaucoma
Inhibition of cytoskeleton regulatory pathway
Netarsudil, Ripasudil
14
S1PR1
Multiple sclerosis
Inhibition of lymphocyte migration
Fingolimod, Ozanimod
15
GLP1R
Type 2 diabetes, Obesity
GLP-1 receptor agonism → Promotion of insulin secretion
Semaglutide, Tirzepatide
16
MAPT
Alzheimer's disease, Parkinson's disease
Inhibition of Tau protein aggregation
TAU360, LMTM
17
PDE10A
Schizophrenia, Parkinson's disease
Regulation of dopamine signaling
Papaverine derivatives
18
KCNQ2/3
Epilepsy
Regulation of neuronal excitability
Ezogabine
19
PDE4/4A/4B/4D/4C
Inflammatory and psychiatric disorders
Inhibition of cAMP degradation → Anti-inflammatory effect
Roflumilast, Apremilast
20
PCSK9
Dyslipidemia
Inhibition of LDL receptor degradation
MK-0616 (oral PCSK9i)
Small Molecule
Antibody
SM-ARS®
No
Target Protein
Indications
Mechanism of Action
Marketed drugs / Pipeline Drugs
1
BCL2
Hematologic malignancies (CLL, AML, etc.)
Inhibition of apoptosis-regulating protein
Venetoclax
2
BTK
B-cell lymphoma, Autoimmune diseases
Inhibition of B-cell receptor signaling
Ibrutinib, Acalabrutinib, Zanubrutinib
3
CDK2/4/6
Breast cancer, Solid tumors
Inhibition of cell cycle progression
Palbociclib, Ribociclib, Abemaciclib
4
FGFR1/2/3
Cholangiocarcinoma, Bladder cancer, etc.
Inhibition of FGFR signaling
Erdafitinib, Pemigatinib, Futibatinib
5
KRAS
Non-small cell lung cancer, Colorectal cancer
Inhibition of KRAS G12C mutation
Sotorasib, Adagrasib
6
MCLI
Hematologic malignancies
Inhibition of anti-apoptotic protein
S64315, AMG 176
7
MDM2
Solid tumors, Hematologic malignancies
Inhibition of p53 degradation → Activation of tumor suppression
Idasanutlin, BI-907828
8
PIK3CA
Breast cancer, Lymphoma
Inhibition of PI3K-AKT pathway
Alpelisib, Copanlisib
9
TYK2
Psoriasis, Lupus
Selective inhibition of TYK2 in JAK-STAT pathway
Deucravacitinib
10
EGFR
Non-small cell lung cancer, Colorectal cancer
Inhibition of EGFR signaling
Osimertinib, Erotinib, Gefitinib
11
JAK1/2/3/TEC
Autoimmune diseases, Myelofibrosis
Inhibition of JAK/STAT pathway
Rusolitinib, Tofacitinib, Baricitinib
12
NLRP3
Inflammatory diseases
Inhibition of inflammasome
DFV890, Inzomelid
13
ROCK1/2
Fibrosis, Glaucoma
Inhibition of cytoskeleton regulatory pathway
Netarsudil, Ripasudil
14
S1PR1
Multiple sclerosis
Inhibition of lymphocyte migration
Fingolimod, Ozanimod
15
GLP1R
Type 2 diabetes, Obesity
GLP-1 receptor agonism → Promotion of insulin secretion
Semaglutide, Tirzepatide
16
MAPT
Alzheimer's disease, Parkinson's disease
Inhibition of Tau protein aggregation
TAU360, LMTM
17
PDE10A
Schizophrenia, Parkinson's disease
Regulation of dopamine signaling
Papaverine derivatives
18
KCNQ2/3
Epilepsy
Regulation of neuronal excitability
Ezogabine
19
PDE4/4A/4B/4D/4C
Inflammatory and psychiatric disorders
Inhibition of cAMP degradation → Anti-inflammatory effect
Roflumilast, Apremilast
20
PCSK9
Dyslipidemia
Inhibition of LDL receptor degradation
MK-0616 (oral PCSK9i)
Asset Program Use Cases
Rapid proof-of-concept (PoC) validation
Deploy pre-validated candidates immediately to minimize development risks with minimal investment.
Rapid proof-of-concept (PoC) validation
Deploy pre-validated candidates immediately to minimize development risks with minimal investment.
Rapid proof-of-concept (PoC) validation
Deploy pre-validated candidates immediately to minimize development risks with minimal investment.
Enhanced competitiveness in collaborative research and proposals
Leverage AI-analyzed and validated candidates to strengthen competitiveness and enhance partnership success rates.
Enhanced competitiveness in collaborative research and proposals
Leverage AI-analyzed and validated candidates to strengthen competitiveness and enhance partnership success rates.
Enhanced competitiveness in collaborative research and proposals
Leverage AI-analyzed and validated candidates to strengthen competitiveness and enhance partnership success rates.
Enhanced competitiveness in collaborative research and proposals
Accelerate portfolio expansion by incorporating pre-screened novel candidate packages from large-scale in silico screening into your early-stage pipeline.
Enhanced competitiveness in collaborative research and proposals
Accelerate portfolio expansion by incorporating pre-screened novel candidate packages from large-scale in silico screening into your early-stage pipeline.
Enhanced competitiveness in collaborative research and proposals
Accelerate portfolio expansion by incorporating pre-screened novel candidate packages from large-scale in silico screening into your early-stage pipeline.
Syntekabio AI Platform
Ensuring Asset Credibility
Syntekabio AI Platforms Ensuring Asset Reliability
FAQ
What is the timeline?
What is the timeline?
What is the timeline?
Are there any concerns about platform security or data leakage?
Are there any concerns about platform security or data leakage?
Are there any concerns about platform security or data leakage?
Is analysis possible even without target protein structural information?
Is analysis possible even without target protein structural information?
Is analysis possible even without target protein structural information?
Looking for specific targets?
Explore our portfolio of AI-based drug candidates and access detailed data now.
Global Premier AI
Drug Partner
Innovate with us.
Contact Us
Contact Us
© Syntekabio Co., Ltd. All rights reserved.
General Inquiries
Investor Relations / Press
Business Development / Partnerships
Data Center
Family Sites
© Syntekabio Co., Ltd. All rights reserved.
Global Premier AI
Drug Partner
Innovate with us.
Contact Us
Contact Us
© Syntekabio Co., Ltd. All rights reserved.
General Inquiries
Investor Relations / Press
Business Development / Partnerships
Data Center
Family Sites